Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Oligomycin** is a macrolide compound produced by Streptomyces species, primarily used as a research tool due to its potent inhibition of mitochondrial oxidative phosphorylation. Its mechanism of action centers on **blocking the proton channel (Fo subunit) of the mitochondrial F1Fo ATP synthase**, which halts ATP production by oxidative phosphorylation. This inhibition causes a substantial drop in mitochondrial ATP synthesis, impedes electron transport, and in turn induces processes like apoptosis and metabolic alteration in affected cells. Oligomycin is highly cytotoxic in mammalian cells but is also employed to probe mitochondrial function, cell metabolism, and as a toxin payload in experimental antibody-drug conjugates. It has no approved medical use due to toxicity[1][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oligomycin.